Myogenin Regulates DUSP13 to Inhibit Apoptosis Induced by Reactive Oxygen Species.

apoptosis cardiomyocyte myogenin p38 MAPK pathway reactive oxygen species

Journal

Frontiers in bioscience (Landmark edition)
ISSN: 2768-6698
Titre abrégé: Front Biosci (Landmark Ed)
Pays: Singapore
ID NLM: 101612996

Informations de publication

Date de publication:
04 Feb 2024
Historique:
received: 21 06 2023
revised: 21 11 2023
accepted: 11 12 2023
medline: 29 2 2024
pubmed: 29 2 2024
entrez: 29 2 2024
Statut: ppublish

Résumé

Myogenin is well known as a crucial transcription factor in skeletal muscle development, yet its other biological functions remain unexplored. Previous research showed that myogenin suppresses apoptosis induced by angiotensin II in human induced pluripotent stem cell-derived cardiomyocytes, and offered a new perspective on myogenin's role in cardioprotection. However, the detailed mechanism of this cardioprotection, especially under oxidative stress, is still unclear. In this study, hydrogen peroxide (H2O2) was used to generate reactive oxygen species in myogenin-overexpressing cardiomyocytes. The apoptosis was examined by flow cytometry. Transcriptome sequencing (RNA-seq) was performed to identify genes regulated by myogenin. Western blotting was used to detect the protein level of Flow cytometry analysis of apoptosis showed that overexpressing myogenin for 24 and 48 hours decreased the apoptotic ratio by 47.9% and 63.5%, respectively, compared with untreated controls. Transcriptome sequencing performed on cardiomyocytes that expressed myogenin for different amounts of time (6, 12, 24, and 48 hours) identified The present findings suggest that myogenin might attenuate apoptosis induced by reactive oxygen species by up-regulating

Sections du résumé

BACKGROUND BACKGROUND
Myogenin is well known as a crucial transcription factor in skeletal muscle development, yet its other biological functions remain unexplored. Previous research showed that myogenin suppresses apoptosis induced by angiotensin II in human induced pluripotent stem cell-derived cardiomyocytes, and offered a new perspective on myogenin's role in cardioprotection. However, the detailed mechanism of this cardioprotection, especially under oxidative stress, is still unclear.
METHODS METHODS
In this study, hydrogen peroxide (H2O2) was used to generate reactive oxygen species in myogenin-overexpressing cardiomyocytes. The apoptosis was examined by flow cytometry. Transcriptome sequencing (RNA-seq) was performed to identify genes regulated by myogenin. Western blotting was used to detect the protein level of
RESULTS RESULTS
Flow cytometry analysis of apoptosis showed that overexpressing myogenin for 24 and 48 hours decreased the apoptotic ratio by 47.9% and 63.5%, respectively, compared with untreated controls. Transcriptome sequencing performed on cardiomyocytes that expressed myogenin for different amounts of time (6, 12, 24, and 48 hours) identified
CONCLUSIONS CONCLUSIONS
The present findings suggest that myogenin might attenuate apoptosis induced by reactive oxygen species by up-regulating

Identifiants

pubmed: 38420814
pii: S2768-6701(23)01152-8
doi: 10.31083/j.fbl2902049
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

49

Subventions

Organisme : Guangdong Basic and Applied Basic Research Foundation
ID : 2021A1515111152
Organisme : National Natural Science Foundation of China
ID : U2005214
Organisme : National Key R&D Program of China
ID : 2022YFB4600600

Informations de copyright

© 2024 The Author(s). Published by IMR Press.

Déclaration de conflit d'intérêts

The authors declare no conflict of interest. However, it should be noted that Lishi Zhou and Bin Lin are affiliated with Guangdong Beating Origin Regenerative Medicine Co., Ltd. Steps have been taken to ensure that their involvement in this research did not influence the objectivity and integrity of the study findings.

Auteurs

Jing Luo (J)

Department of Cardiovascular Surgery, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 510080 Guangzhou, Guangdong, China.
Guangdong Provincial Key Laboratory of South China Structural Heart Disease, 510080 Guangzhou, Guangdong, China.

Qiang Gao (Q)

Department of Cardiovascular Surgery, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 510080 Guangzhou, Guangdong, China.
Guangdong Provincial Key Laboratory of South China Structural Heart Disease, 510080 Guangzhou, Guangdong, China.

Hailong Qiu (H)

Department of Cardiovascular Surgery, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 510080 Guangzhou, Guangdong, China.
Guangdong Provincial Key Laboratory of South China Structural Heart Disease, 510080 Guangzhou, Guangdong, China.

Shuai Zhang (S)

Department of Cardiovascular Surgery, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 510080 Guangzhou, Guangdong, China.
Guangdong Provincial Key Laboratory of South China Structural Heart Disease, 510080 Guangzhou, Guangdong, China.

Wanwan Zou (W)

School of Medicine South China University of Technology, 510006 Guangzhou, Guangdong, China.

Ping Wang (P)

School of Medical Imaging, Tianjin Medical University, 300203 Tianjin, China.

Lishi Zhou (L)

Guangdong Beating Origin Regenerative Medicine Co., Ltd., 528231 Foshan, Guangdong, China.

Lingling Liu (L)

Pen-Tung Sah Institute of Micro-Nano Science and Technology, Xiamen University, 361102 Xiamen, Fujian, China.

Feng Xu (F)

Pen-Tung Sah Institute of Micro-Nano Science and Technology, Xiamen University, 361102 Xiamen, Fujian, China.

Xiaohua Li (X)

Department of Cardiovascular Surgery, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 510080 Guangzhou, Guangdong, China.
Guangdong Provincial Key Laboratory of South China Structural Heart Disease, 510080 Guangzhou, Guangdong, China.

Bin Lin (B)

Guangdong Beating Origin Regenerative Medicine Co., Ltd., 528231 Foshan, Guangdong, China.

Rong Zeng (R)

Guangdong Provincial First Disabled Veterans Hospital, 510260 Guangzhou, Guangdong, China.

Daoheng Sun (D)

Pen-Tung Sah Institute of Micro-Nano Science and Technology, Xiamen University, 361102 Xiamen, Fujian, China.

Jianzheng Cen (J)

Department of Cardiovascular Surgery, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 510080 Guangzhou, Guangdong, China.
Guangdong Provincial Key Laboratory of South China Structural Heart Disease, 510080 Guangzhou, Guangdong, China.

Jian Zhuang (J)

Department of Cardiovascular Surgery, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 510080 Guangzhou, Guangdong, China.
Guangdong Provincial Key Laboratory of South China Structural Heart Disease, 510080 Guangzhou, Guangdong, China.

Classifications MeSH